...Eisai and Galenea partnered to discover and develop synaptic modulators to treat neurodegenerative diseases. The partners...
...partnered to discover and develop synaptic modulators to treat neurodegenerative diseases. The partners will use Galenea's...
...term. Galenea will receive an undisclosed upfront payment and is eligible for undisclosed milestone payments. Galenea Corp....

...Eisai Co. Ltd. (Tokyo:4523; Osaka:4523) and Galenea Corp. (Cambridge, Mass.) partnered to discover and develop synaptic modulators...
...partnered to discover and develop synaptic modulators to treat neurodegenerative diseases. The partners will use Galenea's...
...oversee development under the one-year deal, which includes an option to extend the deal's term. Galenea...

...Not-for-profit foundation CHDI and Galenea partnered to use Galenea's synaptic transmission drug discovery platform to identify...
...discovery platform to identify synaptic dysfunction associated with Huntington's disease (HD). The partnership will use Galenea's...
...synaptic dysfunctions in neurons derived from in vivo rodent models. The partners will also use Galenea's...

...other CNS diseases. This is the second extension and brings the total committed funding for Galenea...
...resulting compounds, and Galena is eligible for milestones and royalties and retains a profit-sharing option. Galenea...
...candidate to Otsuka expected in 2010 (see BioCentury, Feb. 21, 2005 & Oct. 13, 2008). Galenea Corp....

...the universities will receive an undisclosed upfront payment and be eligible for milestones and royalties. Galenea Corp....

...the Tufts University School of Medicine and the University of North Carolina at Chapel Hill. Galenea...

...lead optimization. The extension brings the total committed funding for Galenea to about $75 million. Galenea...
...and royalties or can exercise an option for profit sharing (see BioCentury, Feb. 21, 2005). Galenea Corp....

...alpha in 2005; received rights to RNAi therapeutics against influenza and other respiratory infections from Galenea Corp....
...City of Hope National Medical Center , Duarte, Calif. Dicerna Pharmaceuticals Inc. , Boston, Mass. Galenea Corp....

...worldwide rights to intranasal teriparatide ( PTH 1-34 ) to treat osteoporosis. I. 2/23/06 - Galenea...